Thu, 24th Sep 2020 08:29
FRANKFURT, Sept 24 (Reuters) - AstraZeneca is still
waiting for the go-ahead from the U.S. drug regulator to restart
the clinical trial of its COVID-19 vaccine hopeful in the United
States, Chief Executive Pascal Soriot said on Thursday.
"We are awaiting to hear their decision," Soriot told a
virtual World Economic Forum discussion.
(Reporting by Ludwig Burger
Editing by Caroline Copley)
(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was ...
(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:
(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announ...
(Correcting company name in headline)
(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsort...
Astrazeneca (AZN)